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ABSTRACT
Litteral, Vaughn. M.S., Department of Biochemistry and Molecular Biology, Wright State
University, 2008. mdm2 Amplification in NIH3T3L1 Preadipocytes Leads to Mdm2
Elevation in Terminal Adipogenesis.
The p53 protein is a tumor suppressor protein that is mutated or non-functional in
nearly all cancers. The Mdm2 protein has the ability to functionally inactivate p53 and these
two proteins have been studied extensively in the context of cellular proliferation. In this
study, expression of the murine double minute 2 (mdm2) gene was examined in the mouse
NIH3T3L1 cell line. Under the proper conditions, the immortalized NIH3T3L1 cells have
the ability to differentiate from fibroblasts to adipocytes (Green et al., 1975). This well
characterized cell line provides an excellent model to study mdm2 in differentiation. While
evaluating the regulation of the mdm2 gene during adipogenesis, it was discovered that
NIH3T3L1 preadipocytes possess a 36-fold elevation of mdm2 mRNA relative to A31 cells,
another Balb/c 3T3 fibroblast cell line that lacks the capacity to differentiate (Berberich et al.,
1999). Based on Southern blot analysis, this increase in mdm2 mRNA is the result of a 60
fold gene amplification (Berberich et al., 1999). This study evaluated how mdm2, p53 and
other associated gene products change as NIH3T3L1 cells differentiate from preadipocytes to
adipocytes. Most surprising, the mdm2 mRNA and protein levels remained high throughout
differentiation and Mdm2 changes localization and interaction with key proteins. This work
further proves adipogenesis can occur in the presence of high levels of Mdm2 expression.
Herein, Mdm2 is shown to preferentially interact with the retinoblastoma protein, pRb, in
terminal adipocytes versus preadipocytes. The p53 mRNA, protein levels and DNA binding
(data not shown) decreased and the results suggest that Mdm2 could have a more p53
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independent role in adipogenesis. Finally, this work leads to future experiments of
determining the importance of high level Mdm2 expression in terminal adipogenesis.
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I. Introduction
A. The mdm2 Oncogene
1. The Discovery and Characterization of the murine double minute 2 (mdm2) gene
The mdm2 (murine double minute 2) gene was initially discovered in the
spontaneously transformed 3T3-DM cell line (Cahilly-Snyder et al., 1987). The 3T3-DM
cell line is a derivative of the immortalized murine fibroblast cell line, BalbC 3T3. 3T3-DM
cells contain 25-30 copies per cell of paired, acentric extra-chromosomal bodies called
double minutes (Cahilly-Snyder et al 1987). To determine what gene or genes on these
double minutes led to transformation of the cell line, Dr. Donna George’s laboratory cloned 3
genes from these 1-2 megabase amplicons (mdm1, mdm2 and mdm3). Each of the three
genes was then tested for tumorgenecity by stable expression of the genomic clones in both
NIH3T3 and Rat 2 fibroblasts (Fakharzadeh et al., 1991). These stable cell lines were then
subsequently tested in athymic mice and the injection sites were then monitored for tumor
formation. The mice injected with mdm2 over-expressing cells formed tumors 100% of the
time (N=16) while tumor formation of the mdm-1 (1/12) and mdm-3 (0/10) over-expressing
cells were rarely or never observed respectively (Fakhazadeh et al. 1991). Subsequently a
mdm2 genomic clone was shown to immortalize primary rat embryo fibroblast (REFs) and,
in cooperation with an activated ras oncogene promoted transformation of REFs (Finlay et al
1993).
The mdm2 gene structure and the gene products have been further characterized to
better understand the functional role of mdm2 as an oncogene. The mdm2 gene itself is
approximately 25 kilobases in size and contains 12 exons with intron sizes ranging from 160
to 5000 bp (Montes de Oca et al 1996). Within the first intron of the mdm2 gene lies the P2
1

promoter. The P2 promoter was subsequently shown to be responsible for the induction of
mdm2 transcripts through p53 transactivation (Barak et al., 1994). Alternatively, transcripts
generated from the P1 promoter (upstream of exon 1) are expressed under basal conditions in
a p53 independent manner (Barak et al 1999, Sucedo et al 1998). The P2 derived mdm2
transcripts possesses a shorter 5’ UTR and these transcripts were shown in soft tissue tumors
to be more efficiently translated (Brown et al., 1999). The greater efficiency of translation
for this mdm2 transcript may aid in the rapid inactivation of p53 once mdm2 expression is
induced. Multiple unique mdm2 transcripts have been discovered in both mouse and human
cells (Fakharzadeh et al 1991, Oliner et al 1992, Bartek et al., 2007 or Review). The variety
of transcripts is due to the use of alternative internal splice sites as well as the previously
mentioned different promoter usage (Barak et al 1994, Zauberman et al 1995).
B. The Mdm2 Protein
The mdm2 gene can give rise to an array of proteins due to the utilization of multiple
initiation codons, alternative splicing of transcripts and capsase cleavage (Olson DC et al
1993, Marechal V et al 1997). Olson et al (1993) identified and characterized multiple
Mdm2 proteins. They detected at least 4 additional polypeptides besides the full length
Mdm2 90kDa protein ranging from 57-85kDa. (p85, p76, p74, p58-p57). Monoclonal
antibodies demonstrated the presence of common and distinct epitopes within three different
size proteins. The p90/p85 Mdm2 polypeptide has all epitopes detected by the antibodies,
p76/4 is missing epitopes at the N-terminus of the Mdm2 protein (residues 19-50), and
p58/p57 is missing residues at the C- terminus (residues 383-489) of the full length Mdm2
p90 (Olson et al., 1993). The downstream translational start sites within the mdm2 transcript
can result in translation of slower migrating proteins such as the p76/p74 (p75Mdm2);
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whereas, the p58/p57 proteins can either be the result of capsase cleavage sites or alternative
slicing of C-terminal coding exons. In murine cells, production of the p75Mdm2 requires
exon 1 to be used as a 5’ UTR and results from initiation at an internal AUG codon at
position 50 (Mendrysa et al., 2001).

NLS
ACIDIC
NES

ZF

RF

N‐terminus

19

102

181‐185 223‐274
197‐211

438

305‐322

478

Figure 1 The conserved domains of Mdm2. NLS, nuclear localization sequence; NES,
nuclear export sequence; Acidic, Acidic domain; ZF, zinc finger; RF, ring domain.
The full length Mdm2 protein consist of 491 amino acids and has several well
characterized functional domains (See Figure1), which are conserved from humans to zebra
fish (Marachal et al 1997). The Mdm2 amino terminal domain contains the p53 interaction
domain and is sufficient for inhibition of p53 transactivation (Leng et al., 1995). This Nterminal region of the protein has also been shown to bind to E2F1 (1-220 a.a.) and TFIIE (1222 a.a.) (See Figure 2) (Martin et al., 1995, Thut et al., 1997). The conserved nuclear
localization sequence (NLS, 181-185 a.a.) and nuclear export signal sequence (NES, 197211) of MDM2 mediates the ability of Mdm2 to shuttle between the nucleus and the
cytoplasm. (Roth et al 1998). This Mdm2 protein shuttling appears to be important for
several biochemical activities attributed to the protein (Roth et al 1998). The central domain
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of Mdm2 encompasses (221-272 a.a.) and is called the acidic domain based on its high
percentage (40%) of glutamic and aspartic acid residues. The Retinoblastoma protein, pRb,
interaction domain has been identified within this domain (221-274 a.a.). (Xiao et al., 1995).
Encompassed in this region is the ribosomal L5 protein binding site (153-294 a.a.) (Elenbaas
B 1996). In fact, both Mdm2-L5 and p53-Mdm2-L5 complexes can bind specifically to 5S
rRNA (Marechal et al 1994). More recently, interactions of Mdm2 with L11 and L23 have
been demonstrated to activate p53 by inhibiting Mdm2 suppression (Dai and Lu 2004). The
acidic domain is immediately followed by a conserved Zinc Finger domain of the C4 class at
amino acids 305-322. More specifically, this Mdm2 C4 Zinc Finger belongs to a class of
Zinc Fingers (ZF) known as RanBP2/NZF with a defined consensus sequence X(4)-W-X-CX(2-4)-C-X(3)-N-(6)-C-X(2)-C-X(5) where “X” is any amino acid. Removal of this central
acidic region, including the Zinc Finger of Mdm2 resulted in impaired ubiquitination and
degradation of p53 attributed to the second p53 binding site in this domain (Kulikov et al.,
2006, See Review Lindstrom et al., 2007)). The C-terminus contains the conjugating E3
ubiquitin ligase activity where C464 has proved essential for this activity. (Honda et al.,
1997). The ubiquitin E3 ligase allows targeting of p53 for proteasomal degradation.
Further regulation of Mdm2 was suggested by the discovery that Mdm2 undergoes
capsase mediated proteolytic cleavage during apoptosis (Chen et al 1997, Erhardt et al 1997).
The major caspase cleavage product lacks the RNA binding ability; however, this capsase
cleavage product retains the N-terminal p53 binding domain and is still capable of inhibiting
p53 mediated transactivation. The resultant C-terminal cleavage retains RNA binding ability
(Chen et al., 1997). The role of this cleavage product in the cell remains to be revealed.
C. Regulation of p53
4

The Mdm2 protein has also been shown to bind to the tumor suppressor protein, p53,
in rat cells transfected with p53 (Momand et al., 1992) and this discovery provided one
explanation of mdm2 oncogenic potential. The p53 protein is the 53 kDa phosphoprotein
product of the tumor suppressor gene p53. The clinical importance of p53 has been
demonstrated by approximately 50% of all human cancers exhibiting a loss of p53 function
(Hollstein et al 1991). The p53 protein contains 393 amino acids with a central DNA binding
domain (100-300a.a.). The central domain of p53 is a protease resistant core surround by a
C-terminal end responsible for oligimerization and an N-terminal end containing a strong
transcription activation signal (Vogelstein and Kinzler, 1994). Functionally, p53
accumulates in the cell nucleus (Donehower, L.A., Bradley, A. 1993 and Selivanova et al
1995) during cell division or genotoxic stress and subsequently transactivates p53 responsive
genes (Fields et al 1990). The majority of p53 responsive genes ultimately lead to either cell
cycle arrest (Cross S.M. et al 1995, Review Kastan, M.B. et al 2007) or apoptosis (Canman,
C.E. et al 1995, 1997; Review Rodier F et al., 2007). When a DNA damaging event occurs
then p53 has the ability to either halt cell division to allow for repair of the damaged DNA or
p53 has the ability to promote cell programmed death (Review Menedez et al., 2007). Thus
p53 acts as, “Guardian of the genome” by preventing DNA defects to be passed on to
daughter cells (Review Bartek J et al., 2007 and Efeyan A et al., 2007).
Insight into the interaction of p53 and Mdm2 has been gained via deletion analysis of
Mdm2 and p53 proteins; wherein, deletion of Mdm2 amino acids 1-50 eliminated p53
binding and amino acids 19-102 compromises the entire p53 interaction domain. The crystal
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Figure 2 Cellular proteins that have been shown to bind functional domains of Mdm2.
E2F1 (Elenbaas B 1996), TFIIE and TBP (Thut et al.1997, L5 (Elenbaas et al., 1996), L11
(Dai et al., 2006), L23 (Dai and Lu., 2004), pRb (Xiao et al., 1995), MdmX (Tanimura et al.,
1999)

structure of the p53/Mdm2 complex reveals that Mdm2 forms a deep cleft lined with 14
hydrophobic and aromatic amino acids whereby the p53 peptide forms an amphipathic helix
of two and one half turns with its hydrophobic surface inserted into the cleft of Mdm2
allowing for Van der Waals interactions (Kussie et al, 1996 and Chi SW et al., 2005).
Functionally, the interaction of Mdm2 with the amino terminus of p53 results in inhibition of
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p53 transcriptional activity, allowing cellular division to resume (Momand et al 1992, Chen
et al 1993). Expression of the mdm2 gene is induced by a p53 responsive P2 promoter
located near the 3’ end of intron 1 within mdm2 (Barak et al 1994, Zauberman 1995). These
results defined an auto regulatory loop allowing for an increase in the activated levels of p53
leading to enhanced transcription of the mdm2 gene and ultimately increased levels of Mdm2
protein. Once Mdm2 has reached adequate levels p53 is targeted for proteasomal
degradation through the ubiquitin E3 ligase activity of Mdm2 ultimately resulting in the loss
of Mdm2 P2 promoter activity.
D. Mdm2 auto regulatory feedback loop
Timing is critical in the mdm2/p53 auto regulatory feedback loop. Mdm2 is induced
in a p53 dependent manner in response to a variety of signals including DNA damaging
events. p53 and Mdm2 are allowed to co-exist without p53 inhibition through post
translational control; for example, in the event of extended damage mdm2 levels are induced
rapidly and p53 remains constitutively active. Notably Mdm2 and p53 are both
phosphoproteins having multiple potential phosphorylation sites. This is in accordance with
the model upon following genotoxic stress both proteins can be controlled to allow their coexistence and p53 activity. The mdm2 interaction with p53 is necessary for p53 degradation.
Interaction of the p53/Mdm2 complex was also suspected to be regulated through
phosphorylation since Mdm2 is also a phosphoprotein.
Mdm2 inactivation of p53 can occur through two principle mechanisms. The Mdm2
binding domain of p53 contains the transcriptional activation domain (TAD, 18-28 a.a.) and
when bound to Mdm2 results in the physical blocking of the p53 TAD. This physical
blocking of the p53 TAD results in inhibition of critical transcription associated proteins
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(TBP and associated transcription factors) (Momand et al., 2000). Another safeguard Mdm2
utilizes to ensure repression of the p53 TAD is suspected to be through direct physical
interaction with components of the general transcription machinery (Thut et al 1997, Leng et
al 1995). Together these mechanisms provide efficient inactivation of downstream p53
targets (Review, Lapentko and Prives 2006). Further control was revealed upon finding the
binding of Mdm2 to p53 targets p53 for ubiquitination and subsequent proteasomal
degradation (Haupt et al 1997, Kubbubata et al 1997). Therefore Mdm2 not only elicits
transcriptional regulation over p53, but now has demonstrated the ability to target p53 for
proteasomal degradation. A mechanism of Mdm2 mediated p53 degradation was revealed
through the discovery of an Mdm2 in vitro ubiquitin protein ligase (E3) activity (Honda et
al., 1997).
The simultaneous discovery of Haupt et al and Kubbutat et al., in 1997 that p53 is
targeted by proteasomal degradation by Mdm2 shed insight into how that p53 stability is
regulated. Mdm2 promotes p53 degradation by acting as a E3 ubiquitin ligase (Brooks et al.,
2007). The Ring Finger domain (424-496 a.a.) is critical for Mdm2 E3 ligase activity (Fang
et al., 2000 and Honda et al., 2000, Kawai et al., 2007). Substitution of several conserved
lysine residues in the DNA binding domain of p53 diminishes p53 ubiquitination (Chan et
al., 2006). More recently, peptides generated from the p53 DNA binding region (residues
102-292) that also bind the acidic domain of Mdm2 have been shown to inhibit Mdm2
directed p53 ubiquitination (Wallace et al 2006). Residues 92-112 of p53 appear to be
required for Mdm2 directed degradation (Chen et al., 2000) and a neighboring polyproline
region might act to protect p53 from Mdm2 (62-91aa) (Berger et al.., 2001). Finally,
removal of the last 30-40 C-terminal amino acids of p53 impairs Mdm2 degradation
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(Kubbutat et al.,1998). These discoveries allowed for more insight into the function of
Mdm2 E3 ubiquitin ligase activity on p53.
1. Modulating the p53/Mdm2 auto regulatory loop
In order to properly regulate the activities of the cell the inactivation and degradation
of p53 by Mdm2 must be regulated and governors of this regulation are post-translational
modifications and interaction of other associated proteins. Following stress events such as
gamma irradiation and UV exposure, the Mdm2 and p53 interaction is interrupted. This
interruption appears to be regulated by phosphorylation of p53 on Ser-20, located in the
Mdm2 binding domain. This Ser-20 phosphorylation reduces the affinity of Mdm2 for p53
and increases the stability of p53 with regards to these stress stimuli (Chehab et al., 1999 and
Shieh et al., 1997). Check point kinase-2 (Chk2/Cd1) was found to be the kinase responsible
for phosphorylation of the Ser-20 (Chehab et al., 1999). Signaling occurs upon DNA
damage from ATM to Chk2 to p53 phosphorylation ultimately leading to p53 accumulation.
Regarding gamma irradiation Thr-18 is phosphorylated by CK1-like kinase, a posttranslational modification decreasing the binding between p53 and Mdm2 (Sakaguchi et al.,
2000). Phosphorylation of p53 also occurs at the amino and carboxy termini. Ser-15 and Ser37 play important roles in DNA binding activity (Ljungman M, 2000). The phosphorylation
of Ser 15 on p53 has shown to inhibit in vitro interaction with Mdm2 (Shie et al 1997) giving
additional justification for the co-existence of p53 and Mdm2 in damaging events (Siliciano
et al 1997). Recent evidence shows this phosphorylation site also acts as a substrate for ATM
kinase and DNA dependent protein kinase. The C-terminus of p53 is acetylated on Lys
residues to enhance DNA binding and recruitment of transcription factors ultimately
resulting in an increase in transcriptional activity (Luo J., et al., 2004, Li AG et al., 2007).
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Sumoylation has been shown by Gostissa et al., 1999 to play a minor role in increased
activity of p53 with no apparent effect on protein stability.
Post translational modifications of the Mdm2 protein are necessary in the regulation
of the p53/Mdm2 autoregulatory feedback loop (Review, Meek et al., 2003). The Vousden
laboratory demonstrated sumoylation will drive for p53 nuclear export and can regulate the
strength of the p53-Mdm2 interaction (Carter et al., 2007). Wherein the rapid
phosphorylation of Mdm2 occurs by ATM kinase in response to gamma irradiation
(Khosravi et al,. 1999), ATM induces Mdm2 and MdmX phosphorylation, a decreased
activity and stability of these proteins is the result. Meelmeuster et al., discovered a
mechanism for the reduced stability of Mdm2 and MdmX by showing that ATM-dependent
phosphorylation lowers their affinity for the Mdm2/p53 specific deubiquitinating enzyme,
HAUSP (Meulmeester et al., 2005; See Brooks et al., 2007 for Review). In fact in vitro
phosphorylation of Mdm2 occurs with casein kinase, CK2 (Guerra et al 1997) as well as
DNA-PK (Mayo et al 1997). Phosphorylation of Mdm2 by DNA-PK prevents Mdm2
interaction with p53 (Mayo et al 1997). Mayo et al., 2001 also showed the phosphatidyl 3kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. The
mitogen directed Akt activation leads to specific phosphorylation of Mdm2 at positions
Ser166 and Ser186 and nuclear translocation. Once in the nucleus the Mdm2 protein can
block p53 transactivation and export p53 for proteasomal degradation (Mayo et al., 2001).
These post translational modifications of Mdm2 allow for a higher level of control in the
p53/Mdm2 auto regulatory loop.
E. Mdm2 over-expression
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Ablation of tumor suppressor genes ultimately leads to the loss of regulation of the
cell cycle and is a critical step towards tumorigenesis. Inactivation of two key tumor
suppressor genes, pRb and p53, is frequently associated with human cancers. Moreover,
three DNA viruses (papovaviruses, adenoviruses and human papillomaviruses) can transform
cells by targeting just one of these tumor suppressor proteins. In 1995, Xiao et al.,
demonstrated the ability of Mdm2 to physically interact with the retinoblastoma protein
(Xiao et al., 1995). Further functional evidence of overcoming pRb growth inhibition was
performed by over-expression of Mdm2 (Hsieh et al., 1999). This association was evidence
to tie Mdm2 with the ability to physically and functionally interact with two primary tumor
suppressors, pRb and p53. Mapping of the hdm2 (human homolog of mdm2) gene to
chromosome 12 (locus: 12q13-14) is a region often found amplified in sarcomas.
Subsequently, hdm2 was found amplified in greater than 30% of sarcomas tested (Oliner et
al 1992). In fact, amplification of mdm2 is reported in 10% of human cancers from various
sites including lung or stomach (reviewed in Toledo and Wahl 2006). Table I below
demonstrates various cancer types where mdm2 over-expression has been observed.
The four different mechanisms of over-expression in the above tumor types in Table I
are gene amplification (Oliner et al., 1992), chromosomal translocation (Berberich et al.,
1994), increased transcription (Bueso-Ramos et al., 1993 and Watanabe et al., 1994) and
enhanced translation (Landers et al., 1994 and Landers J.E. et al., 1997). Futhermore a single
nucleotide polymorphism in the mdm2 promoter can lead to a 2-3 fold increase in Mdm2
expression and correlates with accelerated tumor formation (Review see Levine et al., 2006
and Toledo and Wahl 2006).
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Table I Cancer types demonstrating mdm2 amplification.
B-cell chronic lymphocytic leukemia, and non
Hodgkin’s lymphomas

Bueso-Ramos et al., 1993

breast carcinomas

Bueso-Ramos et al., 1996

glioblastomas and anaplastic astrocytomas

Reifenberger G et al., 1993, 1994

Liposarcomas

Leach et al., 1993;

malignant melanomas

Poremba c et al., 1995

oral squamous cell

Matsumura et al. 1996

Osteosarcomas

Oliner et al. 1992, Ladanyi M et al., 1993

Rhabdomyosarcomas

Oliner et al., 1992; Meddeb et al., 1996

Soft tissue sarcomas

Oliner et al 1992, Leach et al., 1993, CordonCardo et al., 1994

Uterine sarcomas

Seki et al., 1997

F. MdmX
A homolog of Mdm2, MdmX, has shown in recent years to be intimately involved in
regulating functions of two key tumor suppressors, p53 and pRb. Originally isolated as a
novel p53 interacting protein from a mouse cDNA expression library, MdmX (Mdm4) is the
490 a.a. homolog of the 491 a.a. Mdm2 (Shvarts et al., 1996 and 1997). MdmX has a high
degree of amino acid and structural similarity to Mdm2 (Reviewed in Marine et al., 2007).
One striking difference is the lack of the p53 targeting E3 ligase activity of MdmX as found
in the homologous C-terminus of Mdm2. (Jackson and Berberich 2000). In fact, it was
surprising that with the high degree of Mdm2 homology in the C-terminus of MdmX it did
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not function as an E3 ligase towards p53. The same residues in p53 are required for MdmX
and Mdm2 interaction (Boltzer et al., 1999). Both Mdm2 and MdmX interact with p53
through N-terminal domains.

The basis for the inhibition of p53 by MdmX was

demonstrated by determining the crystal structure of MdmX bound to a 15 residue p53
peptide (Popowicz et al., 2007). The crystal structure was similar for MdmX and Mdm2;
however, the hydrophobic cleft on p53 is significantly altered. A part of this cleft is blocked
by the differing side chains of Methionine and Tyrosine of the p53 binding pocket of MdmX
(Popowicz et al., 2007) versus Mdm2. MdmX was shown to bind to Mdm2 through its ring
finger domain

(Mdm2 424-496 a.a. and MdmX 438-489a.a., Tanimura et al., 1999).

Badciong et al., determined the heterodimerization of Mdm2 and MdmX increased E3
ubiquitin ligase activity directed to p53 (Badciong et al., 2002). Also heterodimers of the
two proteins showed increased stability versus either homodimer.

Mdm2 directs the

ubiquitination of MdmX as well as itself (deGraaf et al.2003, Kaiwa et al., 2003, Pan and
Chen 2003). Although Mdm2 and MdmX heteroduplex binding of p53 is synergistic, each
protein can bind p53 independently (Badciong et al., 2002). Furthermore, MdmX blocks p53
transactivation by binding to the N-terminal transactivation domain (Shvarts et al., 1996).
More recently MdmX has been shown to interact with other cellular proteins. MdmX
has the ability to bind the cyclin dependent kinase inhibitor, p21, and Mdm2 and MdmX
independently and co-operatively regulate the proteasomal mediated ubiquitin independent
degradation of p21 at G1 and early S-phase (Jin et al., 2008). In addition, ablation of p21 has
shown to rescue a G1 arrest caused by depletion of Mdm2 and MdmX in a p53 null
background (Jin et al., 2008). The retinoblastoma protein, pRb, has also shown to be bound
by MdmX and results in inhibition of Mdm2 mediated pRb ubiquitination and down
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regulation (Uchida et al., 2006). MdmX does have the ability to bind pRb in the presence of
Mdm2 and p53. However, no detectable endogenous MdmX expression has been recorded
in the presence of amplified Mdm2.

MdmX siRNA has been shown to decrease the

endogenous levels of pRb in the presence of Mdm2 and MdmX over-expression has been
shown to stimulate pRb functions (Uchida et al., 2006). Mdm2 and MdmX compete to bind
to pRb in mouse embryo fibroblast (MEF), where MdmX binds pRb independent of the
presence of Mdm2 or p53 (Uchida et al., 2006). Post translational modifications, such as
sumoylation, ubiquitination and phosphorylation, are factors in MdmX stability and activity.
Sumoylation also appears to be a means of regulation, where Sumo-1 conjugation reported
on residues K25, K379 and Sumo-2 on residues K254 and K379 are sites of demonstrated
sumoylation (Pan and Chen 2005). Basal phosphorylation of MdmX on S96 and S289 by
Cdk1 and Ck1-α respectively has been reported (Elias et al., 2005 and Chen et al., 2005b).
This phosphorylation of Mdmx S96 is required for Mdm2 nuclear export; whereas Ck-1α
mediated phosphorylation stimulates the MdmX-p53 interaction (Elias et al., 2005). MdmX
is phosphorylated at residue S367 by Akt and leads to its stability and subsequent Mdm2
stability (Lopex-Pajares et al., 2008). MdmX was shown to inhibit E2F1 transactivation in a
p53 and pRb independent manner (Wunderlich et al., 2004). Although direct interaction of
MdmX was not detected, over-expression of MdmX resulted in destabilized DP-1 and
cytoplasmic accumulation of E2F1 (Wunderlich et al., 2004). Collectively these studies
demonstrate the impact that MdmX has on two key tumor suppressor proteins, p53 and pRb.
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Figure 3 The conserved domains of MdmX. N-terminal p53 interaction domain (19-202
a.a); Acidic, is the acidic domain (223-274 a.a); ZF, zinc finger (305-322 a.a); and RF, ring
finger domain (438-478 a.a.).
G. p53 Independence for mdm2
The p53 related roles of Mdm2 have been the primary focus of the extensive body of
studies in the context of proliferation, arrest and apoptosis. The p53 independent roles of
Mdm2 in these states as well as Mdm2 in different states of the cell have not been as
extensively investigated. Construction of mdm2 null genotype leads to early lethality in
mice, however it was shown that mdm2 null coupled with a p53 null genotype lead to viable
mice (Montes de Oca et al., 1995, McMasters et al., 1996). This line of evidence points to
the importance of p53 and mdm2 co-existence, but does not necessarily lead to the deduction
of obligatory dependence. In the well established Saos-2, an immortalized osteosarcoma cell
line devoid of p53 protein, transient mdm2 over-expression allowed for an increase in E2F
transactivation leading to the conclusion that Mdm2 may indeed have p53 independent roles
(Hsieh et al., 1997).
H. Cellular Differentiation
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Considering the lack of information on mdm2 and its role in development, a system
was needed that involved a defined progression in differentiation. In 1974 Green and
Kehinde isolated Swiss NIH3T3 fibroblast clones that were able to undergo a phenotypically
defined differentiation from a fibroblast to an adipocyte (See Materials and Methods).
Terminal differentiation of the NIH3T3L1 cells leads to adipocyte formation over a period of
5-7 days. On day 0, the pre-adipocytes are allowed to reach two days post confluency. At
this time the normal growth media is removed and Differentiation media (See Materials and
Methods) is applied. The cells undergo a clonal expansion over the next two days and on day
3 the Differentiation media is replaced by growth media. The cells start to round up and lose
the fibroblastic projections and the appearance of lipid accumulation on days 4-6 complete
the adipocyte phenotype (See Results Figure 6). Investigation of mdm2 and its role in
adipogenesis is not in keeping with the traditional role of Mdm2. Adipocytes are terminally
differentiated cells which do not undergo mitosis, the context of previous Mdm2 studies.
During differentiation cells exit from the cell cycle at the G1 phase and maintain a
non-proliferative state known as G0. The precise regulation of the entry into a nonproliferative state is critical for cellular differentiation. The deregulation of G0 entry can
potentially lead to the abnormal morphogenesis as well as certain proliferative diseases in
particular carcinogenesis. The molecular mechanisms that determine cell cycle arrest and
terminal differentiation remain poorly understood. The putative notion in mammalian cells is
interaction of cdk4 (cyclin dependent kinase-4) or cdk6 products in combination with three D
type cyclins (D1, D2, D3) and cdk2 in association with cyclin E play pivotal roles in G1 cell
cycle progression. The timing and expression of the pRb kinase activity of Cyclin D is
induced during the delayed early response to mitogenic stimulation, prior to accumulation
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and kinase activity of Cyclin E. These patterns of expression show that cdk cyclin
complexes have distinct roles in regulating G1 progression, where cdk 4, 6-cyclin couples
extracellular growth signals with the cell cycle whereas Cdk2/Cyclin E controls the initiation
of DNA replication.
The kinase activity of CDK4 is primarily regulated post-translationally at the level of
protein-protein interaction by the association of the cyclin D with the CDK4. This negative
regulation is a result of physical association with inhibitory proteins. There are currently
seven cdk inhibitors that block the phosphorylation of the pRb proteins with two multi-gene
families, p21 and p16ink4a, represent these seven inhibitory proteins. Members of the p21
family (p21, p27kip1 and p57kip2) inhibit cdk activity by forming a ternary complex p21Cyclin D-CDK4; whereas, members of the Ink4 family (p15ink4b, p16ink4a, p18ink4c and
p19ink4d) specifically inactivate CDK4 and CDK6 by forming a complex with the cdk, ink4cdk4 blocking the cyclin interaction. The inhibition of the aforementioned kinase activity
leaves pRb tumor suppressor protein in a hypo-phosphorylated state. In the hypophosphorylated state pRb binds and sequesters E2F and prevents G1 cell cycle progression.
I. Retinoblastoma Protein in Adipogenesis
The retinoblastoma gene (RB1) was the first tumor suppressor gene to be
recognized and cloned (Lee et al., 1989). The pRb protein is categorized as a pocket protein
and these proteins are traditionally known for their ability to repress cell proliferation by
blocking the activity of the E2F family of transcription factors (Kowalik et al., 1998). The
physical interaction of these pocket proteins is necessary for pRb repression of E2F and the
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Figure 4– Traditional role for the retinoblastoma in regulating the cell cycle.
Hypophosphorylated pRb sequesters the S-phase promoting transcription factor, E2F1;
whereas cyclin/cyclin dependent kinases target pRb for phosphorylation and release E2F to
bind DP1 and transactivate S-phase promoting gene targets.
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interaction is inhibited by the sequential phosphorylation by the CDK4/cyclinD and
CDK2/cyclin E complexes to encourage S-phase cell cycle progression (Kato et al., 1993).
Multiple studies have implicated pRb in cellular differentiation (Review, Lipinski et al.,
1999). More specifically in adipogenesis, pRb was shown to play a pivotal role in inducing
gene expression of a subset of adipogenic specific transcription factors and direct physical
interaction with the C/EBP (CCAAT/enhancer binding protein) family (Puigserver et al.,
1998). In particular, the PPAR (peroxisome proliferator acceptor receptor) and the C/EBP
families are integral to the commitment to adipogenesis (Totonoz et al., 1994). The
associated retinoblastoma protein enhances the binding of C/EBP proteins to cognate DNA
sequences and promotes transactivation of a C/EBPß responsive promoter in cells (Cole et
al., 2004). This is in stark contrast to the role of transcriptional repressor that pRb plays on
E2F targets (Dalton et al., 1992, Review McClellan et al., 2007). In fact, pRb was believed
to be necessary for adipogenesis to occur; in that, pRb deficient MEF cells would not
undergo adipogenesis in the presence of standard inducers (Chen et al., 1996). Further
supporting these studies, ELF7 pRb null cells would not differentiate under adipogenic
inducers whereas cells pRb (+/+) ELF1 cells would undergo differentiation upon adipogenic
stimuli. More recently, Cre mediated deletion of pRb in adult primary preadipocytes blocked
their differentiation into white adipocytes (Scime et al., 2005 and Review Khidr L and Chen
PL 2006). Although pRb is integral in the targeting of certain transcription targets in
adipogenesis it can be dispensable. In differentiation, pRb null cell lines have shown that
differentiation can occur upon the introduction of PPARγ gene expression (Hansen et al.,
1999). Therefore, it is the regulation of the downstream adipogenic transcription targets of
pRb such as PPARγ that are required in adipogenesis.
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As aforementioned, in pRb null MEFs unable to undergo adipogenesis this block
was overcome by PPARγ over-expression (Hansen et al., 1999). Over-expression of PPARγ
leads to increase adipogenesis. PPARγ was found to be responsible for driving expression of
a subset of adipogenic genes, in particular the fatty acid binding protein, AP2 (Fajas et al.,
1998). In adipogenesis, pRb was shown to directly decrease transcription of PPARγ through
recruitment of the HDAC3, where inhibition of HDAC3 showed a marked increase in
PPARγ. One important observation is the pRb acetylation by CBP/p300 leading to pRb and
Mdm2 association and ultimately the degradation of E1D1 in muscle cell differentiation.
E1D1 binds pRb and p300/CBP and inhibits MyoD target genes possibly by inhibiting the
HAT (Histone Acetyltransferase) activity of p300/CBP.
The cyclins, in particular D3, have been shown to be instrumental in adipogenesis.
Phelps et al., 1998 demonstrated an increase in Cyclin D3 expression in NIH3T3L1
fibroblast upon differentiation induction. Also, it was reported the switching of associations
of the cyclins and cyclin dependent kinases occur during the stages of NIH3T3L1
differentiation. CyclinD1 was shown to be repressed by PPAR γ following mitogenic
stimulation, whereas Cyclin D3 bound to cdk4 or cdk6 was active. Cyclin D3 was shown
recently to be a coactivator of PPAR γ, capable of phosphorylating the AB domain of the
PPAR γ nuclear receptor (Sarruf et al., 2005). This study also showed that cyclin D3 null
mice were protected from obesity and that siRNA cyclin D3 knockdown experiments had
marked affects on PPAR γ activation and subsequently adipogenesis (Wang et al., 2005).
Cyclin D3 maintains the growth inhibitory activity of C/EBPα (Wang et al., 2005). Due to
insulin treatment, the Akt pathway is activated and acts in de-phosphorylation of C/EBPα
Ser193 through activation of PP2A. The de-phosphorylated C/EBPα recruits the
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retinoblastoma protein freeing E2F and allowing for S-phase progression. Mdm2 has also
been shown to be targeted for nuclear localization by Akt phosphorylation following
mitogenic stimulation.
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Figure 5 Protein interaction partners of the retinoblastoma protein Rb A, B and C domains
of the retinoblastoma protein. LXCE- is a common motif among proteins that bind the AB
domain; KXLKXL, C domain. E2F (Nevins et al.1991, ), C/EBPα and C/EBPß (Sdek et al.,
2004; C domain Mdm2 (Xiao et al., 1995) c-abl (Wen et al. 1996 ).

J. Mdm2 in Adipogenesis
Herein is the investigation into a non-proliferative role of the Mdm2 oncoprotein.
This study evaluates the expression of Mdm2 and known associated protein binding partners
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throughout the differentiation of the NIH3t3L1 cell line. The clinical significance of mdm2
gene amplication as a prognostic marker in liposarcomas (Muller et al., 2007), along with the
implication of the Mdm2 protein interaction network in adipogenesis prompted further
investigation. Information from these studies can further the understanding of mdm2 and its
role in developmental processes.
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II. Materials and Methods
A. TISSUE CULTURE
NIH3T3L1, a subline of mouse 3T3 cells, has the capacity to differentiate from
fibroblasts to adipocytes (Green et al 1975). The NIH 3T3L1 fibroblasts were plated on
tissue (10 cm or 15 cm) culture plates in a growth media of filter sterilized Dulbecco's
Modified Eagle's Medium (DMEM with a final concentration of 14.0 mM Glucose) and 10
% (v/v) Fetal Bovine Serum (FBS). The antibiotic gentamicin was used at a concentration of
10µg per liter of media to avoid bacterial contamination. The cells were cultured in an
incubator at a temperature of 37° Celsius in a humidified atmosphere of five percent carbon
dioxide. Cells were stored in liquid nitrogen following re-suspension in 10%
Dimethylsulfoxide and 90% growth media.
The NIH3T3L1 cells were purchased from American Tissue Type Collection (CCL
92.1, ATCC CL173) and labeled as passage one. All stock NIH3T3L1 cells that were
ultimately used in experiments were maintained in a proliferating state (non-confluent). Cells
were passaged via trypsination prior to confluency. All stock cells used in experiments were
not allowed to reach a passage number greater than ten. The prescribed media was changed
every 72 hours.
To allow for differentiation of NIH3T3L1, these cells were allowed to reach a two
day post- confluent state. Upon reaching this post confluent state a small percentage of
NIH3T3L1 cells will spontaneously differentiate, although the remaining population of
confluent fibroblasts require the addition of a differentiation media (day 0). The
differentiation media is growth media supplemented with the following adipogenic inducers:
1 uM Dexamethasone, 5 mM iso-butyl-methylxanthine (pre- dissolved in 95% ethanol) and
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10 mg of insulin per liter of media. The differentiation media is placed on the post-confluent
population of cells for 48 hours. Following treatment with differentiation media the cells
were maintained in growth media as described above.
Following days 2-7 of differentiation, the determination of commitment to
adipogenesis was accomplished by observation of a rounded cell morphology and lipid
globules in the cytoplasm. Cells were stained with Oil Red O, which stains triglyceride
accumulation red to confirm lipid accumulation. Prior to Oil Red O staining, cells were
washed with cold Phosphate Buffered Saline (PBS) 13.7 mM NaCl, 2.8 mM KCl, 8.0 mM
Na2HPO4 and 1.5 mM KH2PO4 with a pH of 7.4. Cells were then incubated at room
temperature with 7 ml of Oil Red O solution (60% of 0.5% Oil Red O saturated in
isopropanol and 40% PBS) cells were washed several times with cold PBS and observed via
phase contrast microscopy.
B. NORTHERN ANALYSIS
RNA isolation was performed using Trizol (Gibco BRL). Following removal of
growth media, 7 ml of Trizol solution was applied to a 100 mm plate of cells. RNA
extraction was performed according to manufacturer’s specifications and total RNA
suspended in 0.1% diethylpyrocarbonate treated autoclaved double deionized water. All
RNA samples were quantitated by UV absorbance at a wavelength of 260 nm. Total RNA
(20µg) was loaded into a 1% agarose RNA borate gel (2.2 M formaldehyde and 1X RNA
borate (1X is 40 mM boric acid, 10 mM sodium borate, 25 mM EDTA , pH=8) for
electrophoresis. The gel was then incubated twice for 15 minutes each at room temperature
in a neutralizing solution (1M Tris, pH 8, 1.5M NaCl). The total RNA was then transferred

24

overnight to a Nytran membrane (Schleisher and Schuell) via capillary action in the presence
of 2XSSC (1X = 0.15 M NaCl, 15mM NaC6H5O7.H2O). The membrane was then rinsed
twice in 2XSSC to remove any agarose. Next, the RNA was crosslinked to the membrane by
exposure to ultraviolet light (0.120 Joules). The membrane was allowed to dry overnight.
The membrane was blocked with a pre-hybridization solution (6X SSC, 1% sodium
dodecylsulfate (SDS), 0.2% Bovine Serum Albumin, 0.2% polyvinylpyrolidine with 0.5
mg/ml of sheared salmon sperm DNA) by placing the filter in a Roller Derby ™ bottle and
allowing it to rotate for 24 hours at 42.5.C. Random prime 32P dCTP labeled specific DNA
probes were generated according to Gibco BRL Klenow specifications using Sephadex G-50
used for centrifugal separation of unincorporated 32P dCTP from 32P dCTP incorporated
into DNA molecules. After the incorporated 32P labeled probe was collected, 0.5ml of
hybridization solution (40% formaldehyde, 1% SDS, 6X SSC and 0.5 mg/ ml of salmon
sperm DNA) was added to the total 50 ul of labeled DNA probe (specific activity > 109
cpms/ug DNA) and boiled for 5 minutes. The denatured radioactive DNA probe and
hybridization solution was then incubated with the membrane for twenty four hours at
42.5°C with rotation. The unhybridized DNA probe was next removed and the membrane
was washed with rotation two times for thirty minutes at 42.5°C with 1X SSC. Next, the
membrane was placed two times for 30 minutes at 65°C with agitation in 0.1X SSC. Signal
and background were determined to be appropriate with the Geiger counter. The washed
membrane was placed to X-Ray film with an intensifying screen for the indicated times. A
PhosphoImager was used to quantitate the reported signals. The hybridized probe was
stripped from the membrane by adding boiling water for 15 minutes.
C. SOUTHERN ANALYSIS
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Genomic DNA was isolated from the various cell lines as previously reported
(Berberich and Cole 1994). Ten micrograms of genomic DNA was digested to completion
with the indicated restriction endonuclease and separated on a 0.8% agarose/1XTBE gel
containing 0.5 mg/ml ethidium bromide. The DNA was transferred to a Nytran membrane
and probed sequentially with P32-labeled mdm2 and max cDNAs. Hybridization and washing
conditions were as described above for northern analysis and exposed to Kodak XAR film for
1-5 days. Autoradiograph signal intensities were quantified using a Molecular Dynamics
phosphoimager.
D. WESTERN ANALYSIS
Cells were scraped and pelleted followed by two washes with PBS and frozen at -80°C
for at least 1 hour. Cell pellets thawed on ice in approximately two volumes of single lysis
buffer (50mM Tris (pH=8), 150 mM NaCl, 1% NP-40, 1ug per ml of aprotinin and 100 ug/ml
of PMSF) for 30 minutes. The whole cell lysates were then cleared by centrifugation. Whole
cell protein concentrations were then determined by Bradford Assay (BioRad) with bovine
serum albumin used as a standard. Equivalent amounts of protein for each sample was diluted
with 2X SDS PAGE loading buffer (1X = 1M Tris (pH=6.8), 10% B-mercaptoethanol, 5%
SDS, 0.02% bromophenol blue, 40% glycerol) followed by boiling the samples for 5 minutes.
Fifty to 100 ug of total soluble protein from each of the samples was separated by
electrophoresis through a 10% polyacrylamide gel in a buffer of 0.5M Tris, 50mM glycine,
0.1% SDS and a pH=8.3 and then transferred to a polyvinlydine flouride membrane. In
preparation for transferring the proteins, the gel was placed in transfer buffer (25mM Tris,
192mM glycine, 20% methanol, pH=8.3) for 15 minutes in order to equilibrate the gel and to
remove any excess SDS in the gel. The membrane was soaked in methanol for 30 seconds,
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then deionized water for 2 minutes and finally in transfer buffer for 15 minutes. The tank
transfer of the proteins was performed in a transfer buffer at 0.1 amp overnight followed by 1
amp for 1 hour with cooling. The membrane was then air dried at room temperature
overnight. Next, the membrane was re-hydrated in 100% methanol for 30 seconds.
Following hydration, the membrane was then blocked in 10% non-fat dry milk with 0.2%
Tween-20 in phosphate buffered saline at a pH of 7.4 for a minimum of one hour up to 24
hours. The membrane was then placed in 2.5% nonfat dry milk with 0.02% Tween-20 in
phosphate buffered saline at a pH of 7.4 with an appropriate primary antibody dilution. The
following is a list of primary anti bodies: SMP-14 is a monoclonal antibody purchased from
Santa Cruz Biotechnology that was generated from the human epitope 158-172 of the hdm2
protein. The polyclonal Mdm2 antibody was generated in rabbit against the C terminal
portion (133-491 a.a.) of the Mdm2 protein; PAb421 is a p53 monoclonal antibody purchased
from Oncogene and generated from the epitope 371-380 a.a. of the human p53 protein. The
FL-393 is a polyclonal antibody generated in rabbit from the full 393 a.a. of the human p53
protein (β-mercapatoethanol was withheld from the immunoprecipitations indicated to prevent
the disulfide bonds of the heavy and light IgG chains of the immunoprecipitating antibody
from disassociating; since the light chain many times reacts with the antibody used in western
detection masking the detection of proteins in the 45-55 kDa range). The pRb monoclonal
antibody was purchased from Pierce and was generated from the epitope 400-480 a.a. of the
human retinoblastoma protein. The beta actin monoclonal antibody was purchased from
Sigma and generated from the full length protein in mouse. The p21 (WAF1) PAb is a
polyclonal antibody purchased from Santa Cruz and was generated from the C-terminus of the
human p21 protein. WAF1 is a monoclonal antibody purchased from oncogene generated
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from the 90-109 a.a. epitope in mouse. The membrane was then washed three times for 15
minutes in 2.5% nonfat dry milk with 0.02% Tween-20 in PBS to remove non-specific
antibody binding to the PVDF. membrane. The appropriate secondary antibody (1:5000 to
1:40,000) either a goat anti-mouse or goat anti-rabbit antibody conjugated with horse radish
peroxidase (Promega) was then placed on the membrane in 2.5% non-fat dry milk with 0.02%
Tween 20 in P.B.S for a minimum of 15 minutes to a maximum of 4 hours. The membrane
was then washed as previously mentioned. The HRP activity was detected by using one of
the chemilumniscent substrates Pierce Ultrasignal or a compounded coumaric and luminol
luminescence detection solution (250 mM Luminol (3-aminopthalydrazide), 90 mM coumaric
acid in 1 M Tris pH = 8.5) the membrane was then wrapped in Saran wrap and subsequently
exposed for the appropriate time (15 sec to 45 min) to Fuji XAR film.
Antibody was removed from the membrane by washing the membrane in stripping
buffer (100 mM beta-mercaptoethanol, 2% SDS, 62.5 mM Tris-Cl pH=6.7)) and incubated at
60-65 °C for 30-60 minutes with occasional agitation. The membrane was then washed twice
in PBS-T (PBS with 0.1% Tween-20) for 15 minutes each wash. The membrane was then reblocked and the detection was performed as previously described.
E. IMMUNOPRECIPITATION
Each whole cell extract sample was isolated as described before. The whole cell
lysates (0.5-1mg) were cleared for 1 hour at room temperature with rotation using 20 µl of
Protein G agarose purchased from Gibco BRL. The Protein G agasose was pelleted and next,
the supernatant was exposed to 20 µl of primary antibody (See Western Analysis for
description) all with stock concentration of 100 µg/ml; Rb-1 PAb is a monoclonal antibody

28

purchased from oncogene that was used exclusively for immunoprecipitation) with rotation
overnight at 4°C. Following this the samples were exposed to 25 µl of Protein G agarose for
1-2 hours at room temperature with rotation. Next, the Protein G agarose pellets complexed
to immunoreactive proteins were then diluted with an equal volume of 2X SDS page loading
buffer and boiled for 5- 10 minutes. Finally the supernatant was loaded onto a SDS PAGE gel
for subsequent western analysis.
F. S35 METHIONINE PROTEIN LABELING
The cells were radiolabeled with S35 methionine for 1h in growth media lacking
methionine. Whole cell extracts containing equivalent TCA-precipitable counts (107
cpms/reaction) were initially precleared with protein G agarose (Gibco/BRL), then
immunoprecipitated with monoclonal antibodies to Mdm2 (Smp14), p53 (pAb421;
Calbiochem, San Diego, CA) or β-actin (Sigma, St. Louis, MO). Protein G agarose (25µl)
was added and the Ab:PGA complex was washed three times with 50 mM TRIS (pH=7.4,
5mM EDTA, 1% NP-40, and 5% sucrose. The immunoprecipitated samples were
resuspended in SDS PAGE loading buffer and resolved on a 10% SDS PAGE gel. The gel
was treated with Entensify (NEN, Boston, MA), dried under vacuum and exposed to Kodak
XAR film with an intensifying screen for 5-7 days.
G. IMMUNOFLUORESCENCE.
For immunofluorescence assays, NIH3T3L1 were initially seeded onto four well
chamber slides (LAB-TEK) at a concentration of ~10 000 cells/well 2 days prior to
confluency. Following this, cells were fixed in PBS with 3% paraformaldehyde for 8 min at
room temperature and subsequently permeabilized in PBS with 1% TritonX-100 solution for
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20 min at room temperature. Cells were then blocked at 4 C overnight in PBS solution
containing 10% goat serum and 0.2% Tween-20. Primary antibody was incubated for 1 h at
room temperature at a dilution of 1:250-500, and the secondary antibody conjugated with
either Texas Red or Cy2 (Jackson Laboratories) was incubated for 45 min at room
temperature at a concentration of 1.0 µg/µL in 1:10 diluted blocking solution. Nuclei were
stained with Hoechst dye 33342 (Sigma) in PBS at a concentration of 25 µg /mL for 5 min at
room temperature and mounted in Gel mount (Biomeda Corp.). Between each antibody or
stain addition, the chambers were extensively washed 5 times with PBS. Mdm2 was detected
with mouse SMP14 (Oncogene Research Products).
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II. Results
Our lab previously reported p53 RNA levels decrease and mdm2 mRNA levels
remain constitutive as F9 teratocarcinoma cells differentiate from embryonal cells to parietal
endoderm cells (Mayo et al., 1996). Using RNA primer extension assays, we determined
that in F9 cells mdm2 mRNA expression is not directed by the p53 dependent mdm2 P2
promoter under either embryonal or parietal states. However induction of wild type p53
protein by exposure to UV did stimulate mdm2 mRNA expression initiated by the P2
promoters (Mayo et al., 1996). To examine the interplay of p53 and Mdm2 in another cell
culture differentiation system we initiated a study to examine the p53/Mdm2 pathway in
NIH3T3L1 preadipocytes.
A. NIH3T3L1 Adipogenesis.
In 1974 Green et al., identified a NIH3T3 immortalized sub-line, NIH3T3L1, and
demonstrated the ability of this cell line to differentiate into terminally differentiated
adipocytes (Green et al., 1974). Adipogenesis is defined by distinct changes in the
phenotype of NIH3T3L1 cells (See Figure 6). In Figure 6 Panel A, the actively dividing
fibroblasts are passaged prior to 70% confluency and the cells are maintained in Dulbeco’s
Modified Eagle Media with 10% fetal bovine serum (FBS). A bright field photograph of the
fibroblast in the confluent state demonstrating the ability of the NIH3T3L1 to be maintained
in a contact inhibited state in growth media (a small percentage of these fibroblast do have
the ability to undergo spontaneous differentiation), (PanelB). Upon confluency, the
differentiation media is added for two days to allow for adipogenic induction then replaced
by 10%FBS/DMEM. Chemical induction of the contact inhibited NIH3T3L1 preadipocytes,
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Figure 6 Bright field images of NIH3T3L1 cells. All of the samples were cultured as
described in the Material and Methods. Images were photographed at 100X magnification.
Panel A: Morphology of the NIH3T3L1 pre-adipocyte. This panel contains actively dividing
NIH3T3L1 fibroblast at approximately 30% confluency. The arrows direct toward the
fibroblastic projections indicative of an actively dividing fibroblast. Panel B - Confluent,
pre-adipocytes seven days post-confluent stained with Oil Red O, arrows exhibiting contact
inhibition and no visible triglyceride accumulation. Panel C: NIH3T3L1 cells 7 days postdifferentiation. Lipid globules are indicative of adipogenesis. Small arrows indicate the
typical appearance of an NIH3T3L1 adipocyte. Panel D: Stained Oil Red O terminally
differentiated NIH3T3L1 cells on 7th day of differentiation. The arrow demonstrates the
round morphology indicative of adipocytes and cytoplasmic triglyceride accumulation
stained red.
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results in a period of clonal expansion and subsequently a commitment to the differentiation
pathway. In Figure 1 Panel C is a bright field image of terminally differentiated adipocytes
observed in post day 5 of spontaneous differentiation), (PanelB). Upon confluency, the
differentiation media is added for two days to allow for adipogenic induction then replaced
by 10%FBS/DMEM. Chemical induction of the contact inhibited NIH3T3L1 preadipocytes,
results in a period of clonal expansion and subsequently a commitment to the differentiation
pathway. In Figure 1 Panel C is a bright field image of terminally differentiated adipocytes
observed in post day 5 of differentiation. The rounded morphology of the adipocytes in Panel
C along with the lipid droplets in the cytoplasm is in stark contrast to the elongated fibroblast
with projections located in Panel A. The most striking characteristic of the terminally
differentiated adipocyte is the lipid laden cytoplasm, wherein apparent globules rapidly
accumulate triglyceride. In Panel D an Oil Red O stain was used to detect triglyceride
accumulation as shown by the dark stain in the cytoplasm of the terminally differentiated
adipocytes.
B. C/EBP α Induction is a Marker of Adipogenesis.
As a confirmation that the 3T3L1 cells were differentiating into adipocytes, extracts
from NIH3T3L1 cells exposed to differentiation media for 0-7 days were subjected to
Western Analysis. C/EBPα protein levels have been shown to increase in differentiated
NIH3T3L1 cells (Christy et al., 1989). Whole cell extracts were isolated from the days
indicated and used in Western Analysis the two isoforms p42 and p30 that are indicative of
NIH3T3L1 differentiation were detected using a polyclonal antibody to confirm terminal
differentiation (Figure 7). The morphology changes, along with positive triglyceride staining
and
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Figure 7 Western blot of C/EBPα expression during NIH3T3L1 differentiation. 50 µg
of whole cell extracts were isolated from NIH3T3L1 during differentiation on each day
indicated. The protein was normalized to total protein as determined by a Bradford assay
(data not shown) and β-actin expression was used for normalization of protein loading. The
day -1 was not exposed to differentiation media. There are two isoforms of C/EBPα present
(42kDa and 30kDa).
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demonstration of increased C/EBPα expression effectively showed that the NIH3T3L1 cells
differentiated.
C. Northern analysis of mdm2 in 3T3L1
The mdm2 gene null genotype results in lethality for mouse embryos and is rescued by
the combinatorial p53 null genotype (Jones et al., 1995). This observation is in contrast to
the observation of the constitutive mdm2 mRNA and protein and decreasing p53 mRNA
observed in F9 differentiation (Mayo et al., 1996). We sought to determine a baseline mdm2
mRNA expression as compared to previously characterized cells (Berberich et al., 1994) .
While investigating the expression of mdm2 in the 3T3L1 cell line, northern blot analysis
was performed to determine the expression of mdm2 with respect to A31 Balb/c 3T3
fibroblast cells and SP2 murine B cell tumor cells. The SP2 cell line was previously shown
to over express mdm2 mRNA as a result of an amplified, chromosomal translocation
(Berberich et al., 1994). To our surprise, the mdm2 mRNA levels in undifferentiated 3T3L1
cells were 36 fold higher than A31 fibroblast and 1.6 fold increased relative to SP2 cells
(Berberich et al., 1999 and seen in Figure 8). To date, this result represents the first reported
immortalized and non-transformed cell line over-expressing mdm2 mRNA (Berberich et al.,
1999).
D. Southern analysis of mdm2 in NIH3T3L1
The elevated mdm2 mRNA in NIH3T3L1 as compared to the SP2 cells led us to
examine the genetic basis for over-expression of mdm2 (Berberich et al., 1999). The SP2
cells have been previously shown to harbor an amplified (fourfold) mdm2 gene that has been
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Figure 8 Northern blot analysis of mdm2 gene expression. A. Autoradiograph of a
Northern blot hybridized with a radiolabeled mdm2 cDNA(top), then stripped and
rehybridized with a radiolabeled max cDNA (bottom). The upper 3.2kb transcript represents
full length mdm2 mRNA reported by Fakharzadeh et al., 1991, whereas the smaller 1.8kb
transcript has been detected in murine cells. Figure 8B: Is a histogram determined from 3
independent Northern blot analyses (Berberich et al., 1999). The relative expression was
determined by normalization to the 1.8kb transcript of max, a previously characterized
constitutive gene product (Figure #1 in Berberich et al., 1999).
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Figure 9 Southern blot analysis of the mdm2 gene in NIH3T3L1. PanelA.
Autoradiograph of a Southern blot hybridized with a radiolabeled mdm2 cDNA (top panel),
the blot was re-probed with a radiolabeled max cDNA for normalization (bottom panel). B,
H and E represent BamH1, HindIII and EcoR1 digested genomic DNA. PanelB Southern
blot analysis of the mdm2 gene in NIH3T3, the parental line of NIH3T3L1. Autoradiograph
of a Southern blot hybridized with a radiolabeled cDNA mdm2. B, E and H represent
BamH1, EcoR1 and HindIII digested genomic DNA. Panel C Histogram of relative mdm2
expression in A31, SP2 and NIH3T3L1. The relative mdm2 expression was determined by
dividing the mdm2 hybridization signal with the max hybridization signal. The results are
the average relative amplification from three separate experiments. The absence of mdm2
chromosomal translocations was determined using shorter exposures (data not shown).
(Figure #2 in Berberich et al., 1999)
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translocated to the immunoglobulin Cκ gene creating a t (6:10) chromosomal translocation
(Berberich et al., 1994). To determine if a gene amplification or chromosomal translocation
existed in the mdm2 gene locus, genomic DNA was isolated from NIH3T3L1, A31 and SP2
cells. The respective genomic DNA samples were individually digested with the following
restriction enzymes: BamH1, EcoR1 and HindIII. The digested DNAs were separated by
agarose gel electrophoresis and transferred to nitrocellulose by Southern blotting. The blot
was hybridized with a radiolabeled mdm2 cDNA probe. In Figure 9 Panel A in the top panel,
the amplification of the mdm2 gene shown in the NIH3T3L1 is evident when compared to
A31 Balbc signals and normalized after re-probing the blots with the constitutively expressed
gene, max (Figure9A, lower panel). Based on the average of three separate Southern
analyses, the 3T3L1 cells manifested a 57 fold increase in mdm2 DNA relative to A31 cells
(Figure9B and Berberich et al., 1999). The increase in mdm2 amplification of
NIH3T3L1versus the parental NIH3T3 cell line is shown in Figure9 C. As also
demonstrated in the parental cell line, 3T3, no chromosomal translocations were present in
the 3T3L1cell line with respect to the mdm2 gene as seen by the observed banding patterns
relative to A31. It is of interest to report that the 3T3L1 cells harbor a greater amplification
(57fold) than the mdm2 gene amplification reported initially in the spontaneously
transformed 3T3-DM fibroblasts (25 to 50 fold), from which the mdm2 gene was initially
discovered by Fakharzadeh et al., in 1991 (Berberich et al., 1999)..
E. Mdm2 Expression in NIH3T3L1 in Comparison to another Balb/c 3T3 Fibroblast
Line, A31
Due to the mdm2 gene amplification and elevated mRNA levels in 3T3L1 cells,
Mdm2 protein levels in 3T3L1 fibroblasts were determined and compared to A31 and SP2
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Figure 10 Western blot and immunoprecipitation of Mdm2 proteins. Left Panel:
Western blot analysis of whole cell extracts of actively dividing A31, SP2 and 3T3L1 cells
using a monoclonal antibody, SMP14. The Mdm2 protein was normalized to total protein as
determined by a Bradford assay (data not shown). Right Panel: Mdm2 (lane 1), p53 (lane
2), and ß-actin (lane 3), immunoprecipitations of 35S Methionine-labeled whole cell extracts.
The 50kDa protein immunoprecipited protein proved non-specific by being present in the ßactin lane. (Figure #3 in Berberich et al., 1999)
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cell lines. Western blot analysis was performed on whole cell extracts from sub confluent
A31, SP2 and 3T3L1 cells. The level of Mdm2 protein was detected using a Mdm2
monoclonal antibody (SMP14, epitope a.a. 154-167) (Figure 10). Even though 3T3L1
showed the highest mdm2 mRNA expression the level of Mdm2 in SP2 cells was
approximately four times greater than that of 3T3L1 cells. In the 3T3L1 cells the amount of
Mdm2 was substantially higher than that of the A31 cells. In order to confirm the elevated
Mdm2 in 3T3L1 cells, an immunoprecipitation was performed on 35S methionine labeled
3T3L1 whole cell extracts being exposed to SMP14 (Mdm2), 421 (p53) and a monoclonal
antibody to β-actin as a negative control (Figure 10). In Figure 10, the Mdm2
immunoprecipitation (lane 1, right panel) displays the p90 and p85 isoforms as well as two
faster migrating proteins at approximately 50 and 53 kDa. The p53 immunoprecipitation
(lane 2, right panel) displays 90, 53 and 50 kDa proteins and the β-actin monoclonal antibody
immunoprecipitated (lane 3 right panel) a 50kDa protein. Overall, the Mdm2 western and
immunoprecipitation gave similar Mdm2 expression patterns among the different cell lines,
wherein SP2 had the highest expression of full length Mdm2 followed by NIH3T3L1. Using
NIH3T3L1 cells, RNA primer extension analysis clearly demonstrated that mdm2 transcripts
are initiated through the P1 p53 independent mdm2 promoter and that P2 initiated mdm2
transcripts were undetectable (Berberich et al., 1999 Figure# 4).
F. Expression of mdm2 mRNA during 3T3L1 Differentiation
The embyronic lethality observed in mdm2 deficient mice at 6.5 days old as published
by Jones S. et al. implicated mdm2 in a developmental role (Jones et al., 1995). Montes de
Oca Luna et al. 1995 further showed the mdm2 null lethality could be rescued by a p53 null
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Figure 11 Northern blot analysis of mdm2 during adipogenesis. Top Panel: Levels of
mdm2 3.2 and 1.8 kb transcripts are expressed throughout differentiation. NIH3T3L1 cells
were differentiated through 7 days and confirmed positive for triglyceride staining with Oil
Red O (data not shown) and total RNA was isolated on days 0-6 of differentiation. 20 µg of
total RNA per lane was used for northern blot analysis. Lanes 1-7 represent day 0-6 mdm2
mRNA expression. Full length mdm2 mRNA migrates at 3.2kb with a smaller transcript at
1.8kb. Figure 11 bottom panel- Relative expression of mdm2 3.2 and 1.8kb transcripts was
determined by using a laser densitometer to normalize band intensity relative to that of
constitutively expressed max transcript. Solid black bars represent the 3.2 kb mdm2
transcript expression and white bars represent 1.8kb transcript expression both relative to
constitutive max expression. (Figure# 6 in Berberich et al., 1999)
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background. Following this, Mdm2 expression has been shown to be tissue specific and p53
independent (Leveilland et al., 1998). The constitutive level of expression of mdm2 mRNA
despite decreasing p53 levels in differentiating F9 cells, suggest possible p53 independent
regulation of mdm2 in differentiation (Mayo et al., 1996). Having established elevated mdm2
expression in undifferentiated NIH3T3L1 cell, we next sought to determine the level of
mdm2 mRNA expression during the seven day differentiation of NIH3T3L1 fibroblasts to
terminally differentiated adipocytes. In murine cells the mdm2 gene produces two major
transcripts 3.2 and 1.8 kb in length. We sought to determine the level of mRNA expression
for these transcripts during days 0-6 differentiation. The highest level of expression
respectively was the 3.2 and 1.8 kb transcripts, both transcripts with the ability to be
translated into the full length Mdm2. On day 7, a plate from this experiment was stained
with Oil Red O and tested positive for triglyceride accumulation to confirm terminal
differentiation (data not shown (Material and Methods for RNA isolation and Northern
Analysis). In Figure 11 the levels of mdm2 mRNA throughout adipogenesis are shown. The
mdm2 transcripts (3.2 and 1.8 kb) closely mimic the expression of the constitutively
expressed max 1.8 and 1.7 kb transcripts (Berberich et al., 1992). There are subtle variations
in the expression of each of the mdm2 transcripts. The relative expression of mdm2 is based
on digitizing the mdm2 signal divided by the max signal is seen in Figure 11 bottom panel.
The black bars represent the 3.2 kb transcript and the clear bars represent the 1.8 kb
expression (Figure 11 bottom panel). For instance from day 2 to day 6 of the 3.2kb
transcripts, the relative expression data shows less than two fold increase. The 1.8kb mdm2
transcript shows its highest expression in day 2 and its lowest expression on day 4, resulting
in a two and one half-fold difference in relative expression. Overall, the 3.2 kb mdm2
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transcript is the more dominant transcript during proliferation, quiescence (day 0) and
differentiation (day 6) in NIH3T3L (See Figure 11). Although both transcripts have the
ability to be translated into the full-length protein, each has been shown to demonstrate
different translation efficiencies with the 1.8 kb transcript being the most efficiently
translated (Landers et al., 1994).
G. The p53 mRNA Expression Declines Throughout Differentiation
As previously discussed the mdm2 transcripts in NIH3T3L1 cells are initiated from
the p53 independent P1 promoter (Berberich et al., 1999). A decline in p53 transcript levels
would also be in agreement with the findings of p53 immunoprecipitations performed by
Constance et al. 1996 demonstrating p53 protein decreasing during NIH3T3L1
adipogenesis. We sought to determine if indeed p53 transcript levels were down regulated
during adipogenesis. Northern analysis of p53 demonstrated a rapid decline in mRNA
expression shown in Figure 12 as adipogenesis occurs. The high levels of mdm2 transcripts
in NIH3T3L1 are independent of p53 as previously demonstrated by the low activity of the
mdm2 P2 promoter and p53 mRNA levels are down regulated in NIH3T3L1 differentiation.
H. Mdm2 Protein Expression Patterns During NIH3T3L1 Differentiation
The high level of mdm2 transcripts led us to investigate the expression of the Mdm2
protein during NIH3T3L1 adipogenesis. Whole cell extracts from each day of NIH3T3L1
differentiation were subjected to western analysis (Figure 13). Multiple Mdm2 reactive
proteins were detected in each sample analyzed. A molecular weight marker and a
recombinant polyhistadine tagged Mdm2 protein were used to properly size the putative
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Figure 12 Northern analysis of p53 mRNA during adipogenesis. NIH3T3L1 2 day post
confluent cells were exposed to differentiation media. RNA was isolated from cells every day
during the first 6 days of the differentiation protocol. The cells on day 7 were stained with
Oil Red O to confirm differentiation based on triglyceride staining. Only differentiation
experiments demonstrating greater than 80% of the cells Oil Red O positive at day 7 were
examined. 20 µg of total RNA was used in northern blot analysis protocol. The Nytran
membrane was probed with max and p53 32P radiolabeled dCTP probes as indicated.
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Figure 13 Mdm2 protein expression during NIH3T3L1 differentiation. NIH3T3L1
preadipocytes were differentiated and whole cell extracts (WCE) were isolated on days (-1
indicates no differentiation media day 1), 1, 3, 5 and 7). Fifty micrograms of WCE as
determined by Bradford analysis was separated on a 12% SDS PAGE gel and transferred to
Immobilon-PVDF membrane (Millipore). The membrane was exposed to an Mdm2
polyclonal primary antibody for detection, and ß-actin monoclonal antibody was used for
normalization of protein loading. The solid arrow indicates the full length Mdm2 90kDa,
p90.
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Mdm2 proteins. The p76 Mdm2 isoform represents a protein that is produced from a
downstream ATG (+50) and therefore lacks the N-terminal region that interacts with p53 as
previously reported by Olson et al., 1993. The overall induction of both these proteins is
evident during the clonal expansion period as shown in lanes 1-3 (Figure 13 days 0, -1 and
1). Day 5 demonstrates the approximate 76 kDa protein expression increasing relative to the
p90 isoform and increasing throughout differentiation. In addition, western analysis of whole
cell extracts were performed using a monoclonal antibody directed toward the epitope 158167 of the Mdm2 protein (data not shown).
I. Sub-localization of Mdm2 in the Fibroblast and the Adipocyte
Mdm2 has been shown to target key nuclear localized proteins such as pRb and p53 for
degradation. Since the mdm2 mRNA and protein levels seemed to have little regulation
transciptionally (Figure 11), sub-cellular localization might be another level of functional
regulation for Mdm2 in NIH3T3L1. We sought to determine any difference in sub-cellular
localization in pre-adipocytes versus adipocytes. The bright field images in the bottom
panels of Figure 14 demonstrate the rounded and lipid globule appearance of adipocytes.
The corresponding cells show bright red Mdm2 detection within the top panels of Figure 14,
primarily concentrated in the nucleus of the adipocytes. In the confluent fibroblast, the
presence of Mdm2 is more dispersed between the cytoplasm and nucleus.
J. The p53 Protein Expression Patterns During 3T3L1 Differentiation.
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Mdm2

DNA
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Figure 14 – Immunofluorescence staining of NIH3T3L1 preadipocytes and adipocytes to
determine Mdm2 sub-cellular localization. The lower panels are photographs from using
phase contrast microscopy. The arrow indicates a representative adipocyte, with surrounding
confluent preadipocytes. The appearance of fat droplets is indicative of triglyceride
accumulation shown in spontaneously differentiated adipocytes. Hoechst stain was used to
fluorescently stain the total DNA content of cells, wherein the fluorescent intensity is directly
proportional to DNA concentration. The representative adipocyte (lipid globules lower panels)
indicates that the Mdm2 protein appears to be concentrated predominantly in the nucleus of
adipocytes, whereas the confluent fibroblast shows equal distribution in both the cytoplasm and
nucleus.
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The adipogenic transcription factor, C/EBPα, was shown to activate gadd45 (Growth Arrest
and DNA Damage protein 45) in NIH3T3L1 (Constance et al., 1996). This cell cycle arrest is
independent of p53, however C/EBPα is not detectable in western analysis until day 3 of
differentiation. As aforementioned, primer extension analysis on mdm2 and its promoters
demonstrated that promoter one, a p53 independent promoter of mdm2, was more active in
3T3L1 pre-adipocytes compared to P2, a p53 dependent promoter, which is active at very
low levels (Berberich et al, 1999). Also, an electrophoresis mobility shift assay (EMSA)
revealed decreased p53 binding to a consensus DNA binding site in terminally differentiated
whole cell extracts versus confluent whole cell extracts (Berberich et al., 1999). In
terminally differentiated NIH3T3L1 adipocytes p53 is inactive in the context of binding
DNA, an essential function for p53 transactivation. Decreasing affinity of p53 towards
known DNA target sequences suggests p53 might not be required in its traditional role of
maintaining cell cycle arrest during the terminal stage of adipogenesis (days 3-7). Mdm2 has
been shown to block p53 transactivation and target p53 for degradation through
ubiquitination.
Western analysis was performed on whole cell extracts from 3T3L1 cells employing a
polyclonal antibody generated to the full-length p53 protein (FL-393). Recombinant p53 was
loaded in lane 1 to serve as a positive control in order to determine the migration of the
endogenous p53 protein. In Figure 15, the western analysis days 0-6 shows a decrease in p53
protein was observed as cells undergo differentiation (days 4-6), although present throughout
differentiation. This corresponds with a previously reported induction of C/EBPα that
maintains cell cycle arrest in terminal adipocytes (Constance et al., 1996).
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Figure 15 Western blot analysis of p53 levels in NIH3T3L1 differentiation. NIH3T3L1
pre-adipocytes were differentiated days 0-6 and WCE were prepared for each day. 100 ug of
WCE were separated on a 12% SDS PAGE and transferred to an Immobilon (Millipore)
membrane and re-probed with ß-actin for normalization of protein loading. The top arrow
indicates the 53 kDa protein, p53.
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K. Mdm2 Associated with p53 during NIH3T3L1 differentiation
Due to the decreasing levels of p53 and the high level of Mdm2 in adipocytes we
sought to determine if Mdm2 was bound to p53 throughout adipogenesis. In Figure 10
(Right panel) p53 appears to be bound to Mdm2 in actively dividing NIH3T3L1 confluent
cells. In western analysis of p53 in Day 4 -6 there is an increasing slower migrating band
present (Figure 15). Mono-ubiquitination of Mdm2 does lead to decreased DNA binding and
nuclear export, whereas just binding of Mdm2 to p53 is all that is necessary for
transcriptional repression (Brooks et al., 2007). Due to the decreasing protein levels of p53
protein, inactivity of the mdm2 P2 promoter and p53 inability to bind to a cognate DNA
sequence, Mdm2 protein association with p53 was investigated (Berberich et al., 1999).
Whole cell extracts were isolated from NIH3T3L1 cells on the indicated days. Next,
immunoprecipitations of p53 using a monoclonal p53 antibody (Pab421), followed by
western analysis with SMP 14, a monoclonal antibody directed toward amino acids 158-167
of the human Mdm2 protein, were performed. Figure 16 shows Mdm2 that is associated with
p53 as adipogenesis occurs. The co-immunoprecipitated SMP14 reactive proteins migrate at
approximately 90 kDa, the size of the full length Mdm2 protein.
L. Mdm-X Protein Expression During 3T3L1 Differentiation
MdmX heterodimerizes with Mdm2 and protects the p53 protein from its inevitable
fate of Mdm2 association, protein degradation (Tanimur et al., 1999, Jackson et al., 2000).
The concerted attempt to downregulate the production of p53, led us to believe that MdmX
might be regulated in adipogenesis as well. More recently, MdmX was also shown to block
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Figure 16 Immunoprecipitation of p53 followed by western analysis of Mdm2 and p53.
Whole cell extracts, WCE, from NIH3T3L1 were isolated on the day of differentiation
indicated. An equal amount of WCEs were immunoprecipitated with polyclonal Ab421. The
immunoprecipitates were separated by PAGE and transferred onto PVDF membrane for
western analysis by SMP14 (epitope 154-167) for Mdm2 detection and PAb421 for p53
detection.

51

Mdm2 down regulation of pRb (Uchida et al., 2006) and pRb has been shown to be necessary
for adipogenesis (Hansen et al., 1999). Western analysis was performed as indicated in
Figure 17 on whole cell extracts harvested on the day indicated. Actively dividing fibroblast
along with days 0-5 differentiation MdmX expression appeared to be relatively constitutive
throughout differentiation.
M. The p21 (Waf-1) Protein Expression decreases in 3T3L1 Terminal Differentiation
Since p21 is tightly regulated by p53 traditionally, we sought to determine if p21
levels were down regulated or effect Mdm2 associated proteins. p21 acts to inhibit cdks
(cyclin dependent kinases) and exerts its effects directly on PPARγ to block cell
proliferation. The ability of p21 to block cdks allows for a decrease in retinoblastoma protein
phosphorylation and consequently activating pRb in its ability to sequester S phase
promoting transcription factors such as E2F. To assess protein levels, whole cell extracts
from the indicated days of 3T3L1 differentiation were tested by western analysis for p21 and
β-actin protein levels (Figure 18). A biphasic expression of p21 was observed with an
increase early in differentiation (day1) and then dramatically declining by day 4. Based on
these results it appears that pRb should be predominantly be in the hypo-phosphorylated
from days 2-4 and pRb would become hyper-phosphorylated in day 6-7 when the cdk
inhibitor p21 is at its lowest expression in differentiation (Figure 18). The p21 expression
pattern does not correlate with p53 expression patterns. The glucocorticoid, dexamethasone,
(present in NIH3T3L1 differentiation cocktail) has been shown to induce p21 expression
independent of p53 and lead to a decrease in pRb phosphorylation (Ramalingam et al., 1997),
as well as insulin to stimulate p21 stability (Inoeu et al., 2008). Phelps et al., explained
similar findings in NIH3T3L1 that p21 was only transiently expressed in day 2 to day 4
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Figure 17 Western blot analysis of MdmX during adipogenesis. Whole cell extracts were
isolated as indicated each day of differentiation and actively dividing (AD) and then 100ug
was separated by PAGE. The MdmX protein size was determined based on size markers and
rX, His tagged recombinant MdmX and r2, His tagged recombinant Mdm2. The proteins
were transferred to a PVDF membrane and MdmX levels were detected using a polyclonal
MdmX antibody, ß-actin was used for normalization.
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of differentiation and then decreased to undetectable levels by day 7 (Phelps et al., 1998).
They also compared the kinase inhibitor expression patterns between the closely related nondifferentiating cell line, NIH3T3-C2, and NIH3T3L1. The p18INK4c was only induced in
NIH3T3L1 cells and was not seen in NIH3T3-C2, whereas p27Kip1 was seen in both cell lines
(Phelps et al., 1998). This line of evidence, suggests that p18INK4c might be related to cell
differentiation and not the cell cycle arrest of p21 and p27Kip1 and suggest the retinoblastoma
protein might well be in the hypo-phosphorylated state (Phelps et al., 1998 and Ramalingam
et al., 1997).
N. Retinoblastoma Protein Activation in Adipogenesis
As a result of the high level of Mdm2 expression in terminally differentiated cells,
pRb should be inactivated leading to induction of E2F expression. E2F activation is not
typically seen in cells that are terminally differentiated, but is seen in an actively dividing
state of the cell. In light of the down regulation in terminally differentiated adipocytes of p21
(Figure 18), the phosphorylation state of pRb was investigated. The pRb protein in the hypophosphorylated state as previously mentioned interacts with E2F1/DP-1 and functionally
inactivates the ability of these transcription factors to induce known S phase promoting
targets (Martin et al., 1995). Mdm2 also has the ability to complex with the E2F1 and DP-1
transcription factors and Mdm2 has been shown to increase activity of these transcription
factors on S phase promoting targets. Western analysis was performed on NIH3T3L1 whole
cell extracts from actively dividing cells and day 0, 2, 3, 4, 5 and 7 employing a monoclonal
antibody to the retinoblastoma protein. The hyper-phosphorylated form of pRb migrates
slower during SDS electrophoresis, whereas the hypo-phosphorylated form migrates faster
than its counterpart. A distinct difference in migration is observed by contrasting terminally
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differentiated, day 7, vs. actively dividing NIH3T3l1 cells (Figure 19). Thus, in terminally
differentiated adipocytes, demonstrated by Oil Red O staining (data not shown), pRb is
predominantly in the hypo-phosphorylated form whereas the actively dividing 3T3L1 cells
appear to be in the hyper-phosphorylated form.
O. Mdm2 Associations in NIH3T3L1, A Response to pRb Activation
The 90 kDa Mdm2 protein has been shown to bind to the retinoblastoma protein,
pRb, in vitro (Xiao et al, 1995). More specifically, we sought to determine if the
phosphorylation status change of the pRb protein would directly affect the retinoblastoma
protein’s ability to associate with Mdm2. In Figure 20, western analysis was performed with
the Mdm2 monoclonal antibody SMP14 to detect Mdm2 found in the indicated
immunoprecipitates. As mentioned previously, pRb is hypophosphorylated in terminally
differentiated adipocytes (day 7, Figure 19) and pre-dominantly hyper-phosphorylated during
clonal expansion (day1, Figure 19). Whole cell extracts from terminally differentiated
extracts were used to determine the migration of the SMP14 reactive p90 protein. In the first
set of immunoprecipitations marked day 1, starting with lane 2 where a c-Myc antibody was
used to immunoprecipitate two SMP 14 reactive proteins. In lane 3, SMP14 was used in the
immunoprecipitation and afforded one predominant protein of about 90 kDa in size. This IP
was used to positively control the presence of the predominant p90 protein (data not shown).
The faster migrating protein (p76) present in the day 7 whole cell extracts as well as the cMyc and SMP 14 IPs is not present in the 421 monoclonal antibody (p53) IPs leading to the
possibility
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Figure 18 Western blot analyis of p21(Waf1) levels during NIH3T3L1 differentiation.
WCE 50 µg were separated bySDS PAGE then transferred to a PVDF membrane. The
monoclonal antibody to p21 was used and normalized to ß-actin using a monoclonal
antibody.
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Figure 19 Western blot analysis of pRb during Adipogenesis. Whole cell extracts from
NIH3T3L1 were isolated as indicated for each day of differentation. AD represents actively
dividing cells. 100 ug of WCE were separated by SDS PAGE and transferred to a PVDF
membrane and pRB was detected using a monoclonal antibody directed toward pRb. Where
hypo-represents hypophosphorylated pRb and hyper- represents hyperphosphorylated pRb.
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of a possible p76 (N-terminal truncation) identity of this protein. There are also higher
migrating proteins that are immunoreactive to SMP14 greater than 90 kDa (~100kDa). In
day 7 IPs, a 90 kDa SPM 14 reactive protein is co-immunoprecipitated with both the RB-1
and SMP 14 monoclonal antibodies, however in day 1 RB-1 immunoprecipitations this 90kDa protein is not present. The 421 IP also demonstrates two proteins with higher migration
than p90 and are both present in the day 7 SMP 14 IP. Overall, it appears that the p90
protein is the dominant Mdm2 protein associated with pRb in terminal adipocytes.
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Figure 20 Immunoprecipitation of Mdm2 associated proteins followed by western blot
analysis of Mdm2. Mdm2 associations in differentiated (day7) versus non-differentiated
(day1) whole cell extracts. 750 ug of whole cell extracts from NIIH3T3L1 were
immunoprecipitated with the indicated antibodies (c-Myc Ab-1, SMP14, 421 (p53), Waf1
(p21Ab-1) and RB-1 (pRb, the retinoblastoma protein) followed by western analysis for
detection of the Mdm2 proteins associated with the primary immunoprecipitated proteins
with SMP14. Asterick and arrow indicates the Mdm2 p90 protein.
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IV. Discussion
This work represents the characterization of mdm2 gene expression in the NIH3T3L1
cell line. Traditionally the mdm2 gene has been reported in the context of promoting cellular
proliferation, although reports of mdm2 effects can be found in apoptosis and differentiation
states of the cell. In cellular differentiation, the relative mdm2 expression patterns previously
studied appear to vary according to cell type. For instance, Mayo et al., 1996 demonstrated
that mdm2 expression remains at constitutive and basal levels while the F9 teratocarcinoma
cells differentiate into parietal endoderm cells. Alternatively in the differentiation of
myoblast, over-expression of mdm2 is believed to block myogenesis (Fiddler et al., 1996).
Increases in mdm2 mRNA expression were reported in keratinocyte differentiation while p53
levels were decreasing (Dazard et al., 2000). Mostly reported as a regulator of p53, reports
have shown the Mdm2 protein interacts with an increasing cellular network of proteins,
resulting in the control of cell proliferation. Herein is reported elevated mdm2 expression,
localization and interactions in a non-proliferative state of the cell, cellular differentiation.
The mdm2 gene amplification and mRNA over-expression were surprisingly high in
NIH3T3L1 over a 60 fold mdm2 gene amplification and the cell line still maintains its ability
to undergo terminal adipogenesis (Berberich et al., 1999). Furthermore, the over-expressed
Mdm2 protein has the ability to bind to p53 and Rb (Figure 18). This non-transformed
phenotypic setting is in stark contrast to the typical context of mdm2 over-expression seen in
tumor related cell types of plasmacytomas, osteosarcomas, liposarcomas and melanomas
(Berberich et al., 1994, Ladanyi et al.,1993, Quesnal et al., 1994, Leach et al., 1993,
Poremba et al., 1995). One additional phenotype common in tumor cells is the inability to
undergo terminal differentiation. In fact, the most surprising result presented herein was the
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constitutive high level of mdm2 mRNA present during terminal adipogenesis (Figure 11).
Since mdm2 increases transcriptional activation of S-phase promoting genes, one would
predict mdm2 to be down regulated as cells change from actively dividing fibroblast to
terminal adipocytes (Martin et al., 1995). Instead extremely high levels of mdm2 mRNA are
maintained throughout differentiation and in adipocytes (Figure 11). Moreover, the high
levels of mdm2 mRNA expression are approximately 35 fold that of A31 fibroblast and
almost 2 fold more than the transformed SP2 cells, yet NIH3T3L1 cells do not manifest a
transformed phenotype (Berberich et al., 1999). The 3.2 kb transcript of mdm2 was shown to
be more abundant in expression over the other size transcripts (Figure 11). This observation
is in agreement with the primer extension assay, revealing the p53 independent P1 promoter
of mdm2 is responsible for generation of full length mdm2 transcripts (Berberich et al.,
1999). Given that unbound p53 in NIH3T3L1 is higher than SP2 (Figure 10), it was not
expected that the mdm2 P2 promoter activity would be almost undetectable (Berberich et al.,
1999). The primer extension assay to evaluate mdm2 promoter activity demonstrated that the
p53 dependent P2 promoter contribution to mdm2 transcript production was negligible in
non-differentiated pre-adipocytes (Berberich et al., 1999). The P2 generated mdm2 transcript
has a shorter 5’UTR and has been shown to be more efficiently translated than the P1
generated mdm2 transcript and could lead to the explanation of higher protein levels in SP2
plasmacytomas versus NIH3T3L1 preadipocytes (Figure 10) (Brown et al., 1999). In
addition, p53 mRNA and protein levels were shown to decrease by p53 northern and western
analysis (Figure 12 and Figure 15). The p53 protein was also shown to be bound to Mdm2
throughout differentiation (Figure 16). In Figure 10 the western analysis of p53 levels during
adipogenesis, has higher migrating bands in days 4, 5 and 6 and could be due to
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ubiquitination of p53 triggered by Mdm2 association. Further testing using ubiquitin specific
antibodies could be used to determine if p53 ubiquitination is increasing during adipogenesis.
Mdm2 has been shown to target p53 for nuclear export and monoubiquitination or
polyubiquitination depending on the level of Mdm2 present (Brooks et al., 2004). The
growth arrest of terminal adipocytes has been shown to be independent of p53 where
Constance et al., 1996, successfully achieved terminal adipogenesis in the presence of a
dominant negative p53. However, no studies to our knowledge have evaluated the loss of
mdm2 on NIH3T3L1 adipogenesis. Although more recently, Mdm2 was shown to protect
terminally differentiated smooth muscle cells from p53 directed apoptosis (Boesten et al.,
2006). One of the possible roles of over-expressed Mdm2 in the NIH3T3L1 adipogenesis
model could simply be blocking p53 function and ultimately targeting p53 for proteasomal
degradation. This block in p53 function could allow for the ability of other key adipogenic
regulators such as C/EBPα to maintain growth arrest and perform key adipogenic functions,
while avoiding p53 directed apoptosis. Nutlin-3A is a compound that disrupts the p53/Mdm2
interaction and has been shown to lead to p53 directed apoptosis in liposarcomas carrying an
mdm2 amplification (Muller et al., 2007). The importance of Mdm2 suppression on p53
could be further evaluated by exposure of NIH3T3L1 cells to Nutlin-3A. It would also be
interesting to specifically target Mdm2 and determine if mdm2 knockdown experiments
would induce apoptosis or inhibit adipogenesis.
While evaluating p53 expression patterns in 3T3L1, we thought a transactivational
target such as p21 would mimic the expression patterns of p53. However, p21 expression
patterns did not directly correlate with p53 levels. The p21 levels were very low in confluent
pre-adipocytes (day 0, Figure 18) and terminally differentiated adipocytes (day 6, Figure 18).
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A strong induction occurs of p21 on day 1 following addition of IDI and these findings
contradicted the constitutive levels of p21 expression throughout terminal adipogenesis
shown more recently (Inoue et al., in 2008). After further investigation we found Inoue et
al., used 5mg/L of insulin in the post differentiation media. Insulin stimulation of the Akt
pathway leads to stabilization of p21, whereas in our post differentiation media no insulin
was added possibly leading to loss of p21. Also, the PI-3/Akt pathway induced by insulin
treatment in NIH3T3L1 results in cytoplasmic accumulation of p21 (Karishma et al,. 2006)
The putative mechanism of p21 accumulation is thought to occur by blocking nuclear
translocation and 26S proteasome degradation by the Insulin directed Akt phosphorylation
near the NLS leading to p21 cytoplasmic accumulation (Karishma et al., 2006). While our
data did not examine cellular localization of p21, we were able to observe the increase in day
1 following IDI addition and decrease of p21 during terminal adipogenesis.
Actively dividing NIH3T3L1 fibroblasts show a predominant hyperphosphorylated
form of pRb and the terminal differentiated adipocytes show a predominantly
hypophosphorylated pRb (Figure 19). This observation is what one would expect in
terminally differentiated adipocytes that the pRb would be in a hypophosphorylated state
sequestering any free E2F and inhibiting S-phase progression. Alternatively through
induction of the PI-3/Akt pathway, dephosphorylated C/EBPα Ser 193 through PP2A
phospatase has been shown to be responsible for stimulating cell proliferation by recruiting
pRb under mitogenic (i.e. Insulin) stimulation and maintaining the terminal growth arrest in
the absence of mitogenic stimulation as in terminal adipogenesis (Wang et al., 2005).
The Mdm2 protein was recently shown to be a substrate of the Akt/PIP-3 pathway in
NIH3T3L1 following insulin stimulation (Medina et al., 2005). Mayo et al. revealed Mdm2
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translocation from the cytoplasm to the nucleus occurs through the Akt phosphorylation of
Mdm2 at residues Ser166 and Ser186 (Mayo et al., 2000). This translocalization of Mdm2
directed by PIP-3/Akt phosphorylation of Ser166 and Ser 186 residues could account for the
nuclear localization of Mdm2 in adipocytes (Figure 14). Akt phosphorylation of Mdm2 was
shown to stabilize Mdm2 by decreasing Mdm2 self-ubiquitination and comparing addition of
the IDI differentiation cocktail demonstrated an increase of p90 Mdm2 levels in day 1 versus
day-1(no IDI) of Figure 13 (Feng et al 2005). Notably, the levels of mdm2 mRNA do not
appear to change accordingly from day 0 to day 1 and therefore the protein induction is not
likely to be solely attributed to transcriptional regulation. Thus, the terminally differentiated
adipocytes maintain a high level of full length Mdm2 and preferred nuclear localization
compared to the confluent preadipocyte wherein Mdm2 remains primarily cytoplasmic
(Figure 14).
In our estimation the intriguing observation of mdm2 amplification in a sub-line predisposed to undergo spontaneous and hormone stimulated adipogenesis seemed not to be
merely co-incidental. Since the NIH3T3L1 has been shown to harbor a mdm2 amplification,
the possibility exists that genes other than mdm2 on the amplicon might predispose
NIH3T3L1 preadipocytes to adipogenesis (Berberich et al., 1999). One such candidate is
cdk4, which closely neighbors mdm2 and would seem likely to be included on the amplicon
with mdm2. This corresponding chromosomal region (12q13-15) in humans has gained
much interest as a prognostic marker for well differentiated liposarcomas; whereas, benign
lipomas do not harbor this mdm2 gene amplification (Willmore-Payne et al., 2008). Also, in
human studies of these amplified regions the cdk4 and mdm2 (hdm2) genes always belong on
distinct amplicons 12q14.1 and 12q15. In NIH3T3L1 cells, Cdk4 has been shown to be
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necessary for adipogenesis and has been shown not only important in controlling
differentiation but directly interacts with and increases the transactivation of PPARγ,
specifically in the aP2 responsive element (Abella et al., 2005). Thus Cdk4 appears to be
tightly regulated in adipogenesis and no direct evidence does exist of chromosomal
amplification of cdk4 in NIH3T3L1.
Of recent interest is the role of pRb in differentiation with regards to its interaction
with E1D-1 and its mediated repression of CBP/p300 transactivation. In myogenesis, E1D-1
binds to pRb and p300/CBP and inhibits the MyoD target genes possibly by in part inhibiting
the HAT (histone acetyltransferase) activity of p300/CBP. Although Mdm2 is not a
differentiation specific factor, Mdm2 has been shown to direct the E1D-1 proteasomal
degradation when cells exit the cell cycle possibly mediated by the complex pRb-Mdm2 and
is required for normal muscle differentiation. (McClellan et al., 2007; Miyake et al., 2000;
Chan et al., 2001; Guo et al., 2003; Krutzfeld et al., 2005). Nguyen et al., 2004 observed
that pRb acetylation at lysine residues 873/874 increased as myocytes differentiate and pRb
increases Mdm2 association upon increased acetylation resulting in E1D-1 degradation.
Thus an increased association of pRb with Mdm2 as myogenesis occurs. This is consistent
with our observation of increased association of Mdm2 with pRb as in terminal adipogenesis
(Figure 20). In fact in adipogenesis, PPARγ ligand dependent regulation of the C/EBPα
promoter is thought to be regulated by the dislodgement of associated HDAC as well.
Acetylation of the histones might be regulated through PPARγ and the association with
histone acetyltransferases (i.e. p300/CBP) at its N-terminal ligand independent AF-1
transactivation domain (Gelman et al., 1999). The theme of acetylation of differentiation
specific regions of the chromosome regulated by a complex network possibly involving
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Mdm2, pRb and HDAC could be of further interest. Knockdown experiments with Mdm2
siRNA could be used to determine the impact of removing Mdm2 on adipogenesis.
Uchida et al., 2006 observed that MdmX blocks Mdm2 mediated degradation of pRb
and the Mdm2 association with pRb is blocked by the direct interaction of MdmX with pRb.
The MdmX levels increase during exposure to IDI media (days1-2), consistent with LopezPajares findings that insulin treatment stabilizes MdmX (Lopez-Pajares et al., 2008 and
Figure 12). Following the removal of insulin in day 3 there should be a decrease in Akt
activity resulting in as seen herein, a decrease in MdmX (Figure 17). Also, due to the
relatively high level of expression of Mdm2, Mdm2 may be able to overcome an MdmX
block on Mdm2 and pRb interaction. The nuclear localization of Mdm2 possibly directed by
the PI-3/Akt pathway in adipocytes might aid in promoting the degradation of pRb associated
proteins that act as differentiation inhibitors in adipocytes, however, we did not notice any
notable degradation of pRb in adipogenesis (days 0-7) nor did we find any reports in the
literature.
More recently, Perez-Mancera et al., 2007 published their findings to where Slug
modulates adipose tissue mass. In these findings the zinc finger transcription factor, Slug
(Snai2), that triggers epithelial-mesenchymal transitions (EMT) and plays an important role
in developmental processes was tightly regulated during adipogenesis. Their results further
showed that there was a differential HDAC recruitment to the PPARγ2 promoter in a tissue
and Slug dependent manner. Mdm2 has been shown to recruit HDAC. They claimed for the
first time their work has linked EMT critical requirement in adipogenesis. The same group
discovered through microarray analysis and validated with realtime PCR or Western analysis
that mdm2, cdks, the Rb pocket family and HDACs among other targets were under Slug
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dependent regulation (Bermajo-Rodriguez et al., 2006). The higher level of Mdm2 in
NIH3T3L1 could result in a preemptive switch toward adipogenesis in this cell lineage.
V. Conclusion
In conclusion, the work presented herein demonstrates for the first time an
immortalized non-transformed cell line harboring a mdm2 amplification (Berberich et al.,
1999). We have also shown a preferential association of Mdm2 with pRb in day 7 versus
day 1 differentiation. The work further proves adipogenesis can occur in the presence of high
levels of mdm2 expression. The observations of elevated Mdm2 expression during
adipogenesis, taken with a decrease in p53 protein, mRNA and DNA binding (data not
shown) suggest Mdm2 might play a more central role with pRb in adipogenesis. Finally, the
work leads to future experiments of determining the importance of high level Mdm2
expression in NIH3T3L1 differentiation.
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